Centessa Pharmaceuticals plc

NasdaqGS:CNTA Stok Raporu

Piyasa değeri: US$6.3b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Centessa Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 2/4

Centessa Pharmaceuticals CEO'su Mario Accardi, Jan2026 tarihinde atandı, in görev süresi bir yıldan az. şirketin hisselerinin 0.16% doğrudan sahiptir ve bu hisselerin değeri $ 9.85M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2 yıl ve 5.3 yıldır.

Anahtar bilgiler

Mario Accardi

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesin/a
CEO görev süresiless than a year
CEO sahipliği0.2%
Yönetim ortalama görev süresi2yrs
Yönetim Kurulu ortalama görev süresi5.3yrs

Son yönetim güncellemeleri

Recent updates

Analiz Makalesi • Oct 28

Health Check: How Prudently Does Centessa Pharmaceuticals (NASDAQ:CNTA) Use Debt?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Seeking Alpha • Dec 31

Centessa Pharmaceuticals: Orexin Franchise Worth Monitoring

Summary Centessa Pharmaceuticals, founded from the merger of 10 biotech companies, is based on an asset-centric model, primarily developing its lead orexin agonist, ORX-750. ORX-750 targets narcolepsy types 1 and 2 and idiopathic hypersomnia, showing promising phase 1 results, with phase 2 data expected in 2025. Takeda's TAK-861 success partially de-risks ORX-750, making Centessa a potential acquisition target if ORX-750 proves it is best-in-class. With $500M in cash and a runway into mid-2027, Centessa's phase 2 trial results for ORX-750 are crucial for its future valuation. Read the full article on Seeking Alpha
Seeking Alpha • Sep 25

Centessa Pharmaceuticals: Progressing SerpinPC Through Registrational Trials In Hemophilia B

Summary Centessa Pharma's SerpinPC, a subcutaneous biologic inhibitor, shows promising results in reducing bleeding rates in hemophilia B, with a favorable safety profile. Despite the stock doubling in value, I remain cautious due to the company's unclear business strategy and lack of registrational data. The hemophilia B market is competitive with existing treatments. SerpinPC's unique mechanism and delivery method provide niche advantages but face significant competition. With a $2bn market cap and a cash runway of 6-7 quarters, I will avoid investing until there's more clarity on their strategic direction. Read the full article on Seeking Alpha
Seeking Alpha • Apr 24

Centessa: Hemophilia B Data Readout In 2024 Is Major Turning Point

Summary Centessa Pharmaceuticals plc interim data from the PRESent-2 study, using SerpinPC for the treatment of patients with Hemophilia B without inhibitors, is expected to be released in 2024. PRESent-3 is another registrational study using SerpinPC for the treatment of patients with Hemophilia B, however it is for the targeting of such patients with inhibitors. ORX750 is an oral selective orexin receptor agonist being developed for the treatment of patients with Narcolepsy Type 1; Proof of concept data to be released in second half 2024. LB101 is another product in the pipeline with great potential targeting solid tumors, because it utilizes proven targeted proteins such as PD-L1 and CD47; The PD-L1 blockade occurs first as a block mechanism then with hinges dissolving moves the CD47 into place to perform mechanism of action. Read the full article on Seeking Alpha
Seeking Alpha • Oct 20

Centessa Pharmaceuticals snaps multi-day losing streak; up 10%

For the first time since Oct. 13, Centessa Pharmaceuticals (NASDAQ:CNTA) is showing gains. In Thursday afternoon trading, the biotech is up 10%. There is no news or other catalysts that might explain the jump. However, based on a technical analysis, Centessa (CNTA) deviated two standard deviations lower from its mean touching its lower Bolinger Band level and has snapped up higher, back to its mean level. From market close Oct. 13 through market close Oct. 19, shares fell ~15%. Seeking Alpha views Centessa (CNTA) as a hold with high marks for valuation and growth.
Seeking Alpha • Sep 14

Centessa hemophilia B therapy SerpinPC gets FDA orphan drug status

The U.S. Food and Drug Administration (FDA) granted orphan drug designation to Centessa Pharmaceuticals' (NASDAQ:CNTA) SerpinPC to treat hemophilia B. The U.K.-based company said in a Sept. 14 press release that it plans to begin registrational studies of SerpinPC in Q4 2022. SerpinPC is a biological drug candidate, based on the serpin family of proteins which is designed to allow more thrombin to be generated by inhibiting activated protein C (APC), thus rebalancing coagulation in patients with hemophilia, according to Centessa. "We believe SerpinPC has the potential to offer patients with hemophilia B a convenient subcutaneous option that is designed to prevent and reduce bleeds without the risk of thrombosis," said Centessa CEO Saurabh Saha. The FDA grants orphan drug status to therapies which treat or prevent rare diseases that affect fewer than 200K people in the U.S. The designation provides certain incentives, including up to seven years of market exclusivity, if approved.
Seeking Alpha • Aug 10

Centessa Pharmaceuticals GAAP EPS of -$0.69

Centessa Pharmaceuticals press release (NASDAQ:CNTA): Q2 GAAP EPS of -$0.69. Cash and Cash Equivalents: $484.2 million as of June 30, 2022, which the Company expects will fund operations into 2026, without drawing on the remaining available tranches under the Oberland credit facility.
Seeking Alpha • Dec 23

Checking In On Centessa Pharmaceuticals

Today, we put Centessa Pharmaceuticals in the spotlight for the first time. Centessa has a unique business model, multiple potential shots on goal, is deep in Busted IPO territory and has picked up some recent insider buying. A full investment analysis follows in the paragraphs below.

CEO

Mario Accardi (40 yo)

less than a year
Görev süresi

Dr. Mario Alberto Accardi, Ph D., MENG, is Co-Founder, Chairman & Director of Orthonika Limited. He was CEO of Orthonika Limited.He served as President of the Orexin Program at Centessa Pharmaceuticals pl...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
John Crowley
Chief Financial Officer2yrsUS$3.84m0%
$ 0
Stephen Kanes
Head of R&D and Chief Medical Officer1.4yrsUS$6.82m0%
$ 0
Mario Accardi
CEO & Directorless than a yearVeri yok0.16%
$ 9.9m
Raphael Deferiere
Senior VP & Chief Accounting Officer1.1yrsVeri yokVeri yok
Tia Bush
Chief Technology & Quality Officer3.3yrsVeri yok0.054%
$ 3.4m
Kristen Sheppard
Senior Vice President of Investor Relations & Corporate Communications4yrsVeri yokVeri yok
Iqbal Hussain
Chief Legal Officer5.3yrsUS$2.05m0.016%
$ 1.0m
Karen Anderson
Chief People Officer3.6yrsVeri yok0.043%
$ 2.7m
Gregory Weinhoff
Chief Business Officer2yrsUS$3.31m0%
$ 0
Charlene Stoudt
Senior Vice President of Clinical Development Operations1.7yrsVeri yokVeri yok
Kimberly McCormick
Senior Vice President of Regulatory Affairs & Medical Writing1.4yrsVeri yokVeri yok
2.0yrs
Ortalama Görev Süresi
53.5yo
Ortalama Yaş

Deneyimli Yönetim: CNTA 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Mario Accardi
CEO & Directorless than a yearVeri yok0.16%
$ 9.9m
Francesco de Rubertis
Independent Non-Executive Chairman of the Board5.6yrsVeri yokVeri yok
Mary Hedley
Independent Non-Executive Director5.3yrsUS$404.64k0%
$ 0
Brett I. Zbar
Independent Non-Executive Director5.4yrsUS$409.64k0%
$ 0
Arjun Goyal
Independent Non-Executive Director5.4yrsUS$412.14k0.30%
$ 18.7m
Samarth Kulkarni
Independent Non-Executive Director5.3yrsUS$407.14k0%
$ 0
Carol Stuckley
Independent Non-Executive Director5.1yrsUS$414.64k0%
$ 0
Mathias Hukkelhoven
Independent Non-Executive Director3.9yrsUS$399.64k0%
$ 0
5.3yrs
Ortalama Görev Süresi
55yo
Ortalama Yaş

Deneyimli Yönetim Kurulu: CNTA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.3 yıldır).

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/06/25 19:13
Gün Sonu Hisse Fiyatı2026/06/23 00:00
Kazançlar2026/03/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Centessa Pharmaceuticals plc 11 Bu analistlerden 8, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Mayank MamtaniB. Riley Securities, Inc.
Umer RaffatEvercore ISI
Andrea NewkirkGoldman Sachs